Shire’s Exit Strategy from Japan Provides Bayer with Exclusive Product Rights
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 44 (Table of Contents)
Published: 4 Feb-2004
DOI: 10.3833/pdr.v2004.i44.834 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Shire Pharmaceuticals has sold Bayer the exclusive rights to develop, market and sell FOSRENOL® in Japan in a deal worth up to US$70 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS